<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45113">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756326</url>
  </required_header>
  <id_info>
    <org_study_id>PREOB-NU3</org_study_id>
    <nct_id>NCT01756326</nct_id>
  </id_info>
  <brief_title>Phase 2b/3 Study on Autologous Osteoblastic Cells Implantation in Hypotrophic Non-Union Fractures</brief_title>
  <official_title>A Pivotal Phase 2b/3, Multicentre, Randomised, Open, Controlled Study on the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Non-Infected Hypotrophic Non-Union Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bone Therapeutics S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bone Therapeutics S.A</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Netherlands: Ministry of Health, Welfare and Sport</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fracture healing is a complex physiological process caused by interaction of cellular
      elements, cytokines and signaling proteins, which results in the formation of new bone
      (Gerstenfeld et al., 2003). Depending on fracture site, complexity, co-morbidities and other
      factors, 10% of all fractures will eventually fail to unite.

      Non-union fractures are defined as fractures that are at least six to nine months old and in
      which there have been no signs of healing for the last three months. Various causes have
      been evoked for impaired healing in hypotrophic (atrophic and oligotrophic) non-unions,
      including poor fracture stabilization, local infection and failure of the osteoblastic cells
      to multiply. Currently the treatment of choice for non-unions, particularly atrophic
      non-unions, is bone autograft (or allograft), combined or not with intramedullary nailing,
      plating, and external fixation devices (Kanakaris et al., 2007). This procedure produces
      good results but requires an invasive surgery of several hours under general anesthesia and
      a few days of hospitalization. Because of this, major complications have been reported in up
      to 20-30% of patients (Pieske et al., 2009, Zimmerman et al., 2009).

      This Phase 2b/3 study aims at demonstrating the safety and efficacy of PREOB®, a proprietary
      population of autologous osteoblastic cells, in the treatment of hypotrophic non-union
      fractures of long bones. PREOB® will be compared to Bone Autograft in a non-inferiority
      design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Global Disease Evaluation as perceived by the patient using a Visual Analogue Scale</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological healing progression using the RUS(T) as assessed by CT scan</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential occurrence of any AE or SAE, related to the product or to the procedure, using patient open non-directive questionnaire, physical examination and laboratory measurements</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain using a Visual Analogue Scale</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-bearing using Likert Scale</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Well-being score as assessed by the SF-12 questionnaire</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological improvement using the RUS(T) as assessed by X-ray</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Long Bone Non-Union</condition>
  <arm_group>
    <arm_group_label>PREOB® Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will undergo a single administration of PREOB® into the non-union site, under local or loco-regional anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bone Autograft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will be treated by Bone Autograft according to standard-of-care procedure of the investigating site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PREOB® Implantation</intervention_name>
    <arm_group_label>PREOB® Implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Autograft</intervention_name>
    <arm_group_label>Bone Autograft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide a written, dated, and signed informed consent prior to any study
             related procedure, and to understand and comply with study requirements

          -  Diagnosis of a non-infected hypotrophic non-union fracture of a long bone of at least
             6 months at the time of treatment

          -  Normal hematology function

        Exclusion Criteria:

          -  Positive serology for HIV, hepatitis B, hepatitis C, syphilis, HTLV-1

          -  Presence or previous history, or risk factors for diseases caused by prions

          -  Renal impairment, hepatic impairment

          -  Patient with poorly controlled diabetes mellitus, severe arterial diseases and/or
             neuropathy

          -  Insufficient fracture stability

          -  Recent osteosynthesis material or bone graft

          -  Multifocal fracture/non-unions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enrico Bastianelli, MD, MBA</last_name>
    <email>preob.nu3@bonetherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigating site BE01</name>
      <address>
        <city>Anderlecht</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site BE09</name>
      <address>
        <city>Anderlecht</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site BE05</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Desmyter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigating site BE02</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site BE04</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site BE06</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site BE07</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site BE08</name>
      <address>
        <city>Mons</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site BE03</name>
      <address>
        <city>Ottignies</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site FR01</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site FR04</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site FR06</name>
      <address>
        <city>Evry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site FR03</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site FR02</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site NL02</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigating site NL01</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Union Fractures</keyword>
  <keyword>Impaired Healing</keyword>
  <keyword>Fractures</keyword>
  <keyword>Orthopedics</keyword>
  <keyword>Bone</keyword>
  <keyword>Musculoskeletal Disorders</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Ununited</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
